Novavax's Updated COVID Vaccine: A Strong Contender Against Pfizer and Moderna

Novavax's updated Covid vaccine has been authorized for emergency use by the FDA, positioning the company to compete with Pfizer and Moderna in the U.S. Covid vaccine market this fall. The vaccine's broad authorization label, logistical issues with the rollout of other shots, and a growing demand for protein-based vaccines make Novavax's offering an attractive alternative. The arrival of Novavax's vaccine comes at a time when Covid vaccine demand is expected to peak in the U.S., and the company aims to strengthen its financial position by capitalizing on sales of its updated vaccine. However, the overall uptake of Covid vaccines this fall remains uncertain.